Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines

Herceptin is a humanized monoclonal antibody targeted against the extracellular domain of the HER2 oncogene, which is amplified and overexpressed in 10–34% of breast cancers. Herceptin therapy provides effective treatment in HER2-positive metastatic breast cancer, although a favorable treatment response is not achieved in all cases. Here, we show that Herceptin treatment induces a dose-dependent growth reduction in breast cancer cell lines with HER2 amplification, whereas nonamplified cell lines are practically resistant. Time-course analysis of global gene expression patterns in amplified and nonamplified cell lines indicated a major change in transcript levels between 24 and 48 h of Herceptin treatment. A step-wise gene selection algorithm revealed a set of 439 genes whose temporal expression profiles differed most between the amplified and nonamplified cell lines. The discriminatory power of these genes was confirmed by both hierarchical clustering and self-organizing map analyses. In the amplified cell lines, the Herceptin treatment induced the expression of several genes involved in RNA processing and DNA repair, while cell adhesion mediators and known oncogenes, such as c-FOS and c-KIT, were downregulated. These results provide additional clues to the downstream effects of blocking the HER2 pathway in breast cancer and may provide new targets for more effective treatment.

[1]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[2]  W. Cleveland Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[3]  S. Safe,et al.  Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. , 2002, Biochemical and biophysical research communications.

[4]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[5]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Astola,et al.  A strategy for identifying class-separating genes in drug-treatment microarray data , 2003 .

[7]  B. Burg,et al.  Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells , 1989, Molecular and Cellular Endocrinology.

[8]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[9]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[10]  J. Fletcher,et al.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.

[11]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[14]  Michael L. Bittner,et al.  Microarrays: Optical Technologies and Informatics , 2001 .

[15]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[16]  Terence P. Speed,et al.  Normalization for cDNA microarry data , 2001, SPIE BiOS.

[17]  김삼묘,et al.  “Bioinformatics” 특집을 내면서 , 2000 .

[18]  Michael L. Bittner,et al.  Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Esa Alhoniemi,et al.  SOM Toolbox for Matlab 5 , 2000 .

[20]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Teuvo Kohonen,et al.  Self-Organizing Maps , 2010 .

[22]  Jaakko Astola,et al.  Analysis and Visualization of Gene Expression Microarray Data in Human Cancer Using Self-Organizing Maps , 2003, Machine Learning.